<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04191382</url>
  </required_header>
  <id_info>
    <org_study_id>ACT16106</org_study_id>
    <secondary_id>2019-002015-26</secondary_id>
    <secondary_id>U1111-1228-9473</secondary_id>
    <nct_id>NCT04191382</nct_id>
  </id_info>
  <brief_title>Phase 2 Window Study of SAR439859 Versus Letrozole in ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer (AMEERA-4)</brief_title>
  <official_title>Phase 2 Window Study of Two Dose Levels of SAR439859 (SERD) Versus Letrozole in Newly Diagnosed Pre-operative Post-menopausal Patients With ER Positive, HER2 Negative Primary Breast Cancer (AMEERA-4)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To determine whether SAR439859 given at 2 different doses improves the antiproliferative
      activity when compared to letrozole

      Secondary Objectives:

        -  To assess the proportion of participants with a relative decrease from baseline in
           percentage of positive tumor cells tested by immunohistochemistry ≥50% (Ki67≥50%) in the
           three treatment arms

        -  To assess estrogen receptor (ER) degradation in biopsies in participants in the three
           treatment arms

        -  To assess safety in the three treatment arms
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Duration of the study, per patient, will include screening period of up to 14 days before
      randomization, treatment period of 14 days and post-treatment safety follow-up period of 30±7
      days after last Investigational Medicinal Product (IMP) intake.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ki67</measure>
    <time_frame>Baseline and Day 15</time_frame>
    <description>Change in Ki67 (percentage of positive tumor cells tested by immunohistochemistry) after a 14-day treatment period compared to baseline assessed by central reading</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ki67≥50%</measure>
    <time_frame>Baseline and Day 15</time_frame>
    <description>Proportion of participants with relative change from baseline in Ki67≥50% after a 14-day treatment period compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ER Expression</measure>
    <time_frame>Baseline and Day 15</time_frame>
    <description>Change in ER expression after a 14-day treatment period compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)/Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to approximately Day 44</time_frame>
    <description>Percentage of participants with AEs/SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Test Abnormalities</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>Percentage of participants with clinical laboratory test abnormalities</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>SAR439859 dose regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAR439859 dose regimen 1 administered for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAR439859 dose regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAR439859 dose regimen 2 administered for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>letrozole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>letrozole 2.5 mg administered once daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR439859</intervention_name>
    <description>Pharmaceutical form: Capsules Route of administration: Oral</description>
    <arm_group_label>SAR439859 dose regimen 1</arm_group_label>
    <arm_group_label>SAR439859 dose regimen 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole</intervention_name>
    <description>Pharmaceutical form: Tablets Route of administration: Oral</description>
    <arm_group_label>letrozole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Histological or cytological proven diagnosis of invasive breast adenocarcinoma

          -  Localized breast cancer eligible for upfront breast conservative surgery or upfront
             mastectomy: Stage I, Stage II or operable Stage III (excludes T4) as defined in
             American Joint Committee on Cancer (AJCC) Cancer Staging Manual 8th edition 2017

          -  Postmenopausal women as defined by one of the following:

          -  Spontaneous cessation of menses &gt;12 months;

          -  or who have received hormonal replacement therapy but have discontinued this treatment
             and have follicle stimulating hormone (FSH) level in the postmenopausal range;

          -  or with status post bilateral surgical oophorectomy;

          -  or post bilateral ovarian ablation through pelvic radiotherapy

          -  Breast tumor size of at least 10 mm in greatest dimension measured by ultrasound

          -  Primary tumor must be positive for Estrogen Receptors (ER+) and negative for HER2
             (HER2-) receptor by immunohistochemistry

          -  Ki67 level of at least 15% at diagnosis from immunohistochemistry of the tumor

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

        Exclusion criteria:

          -  Medical history or ongoing gastrointestinal disorders potentially affecting the
             absorption of SAR439859 or letrozole; Participants unable to swallow normally and to
             take capsules or tablets

          -  Participant with any other cancer; adequately treated basal cell or squamous cell skin
             cancer or in situ cervical cancer or any other cancer from which the participant has
             been disease free for &gt;3 years are allowed

          -  Evidence of metastatic spread by standard assessment according to local practice

          -  Treatment with strong or moderate Cytochrome P450 3A (CYP3A), CYP2C8 inducers or drugs
             that have the potential to inhibit uridine diphosphate glucuronosyltransferase (UGT)
             within 2 weeks before first study treatment administration or 5 elimination half-lives
             whichever is longest

          -  Ongoing treatment with drugs that are sensitive substrates of P-glycoprotein (P-gp)

          -  Use of any investigational agent within 4 weeks prior to randomization

          -  Recent use of hormone replacement therapy (last dose ≤30 days prior to randomization)

          -  Prior anti-cancer treatment is not allowed unless it was completed at least 1 year
             prior to inclusion into this trial

          -  Previous systemic or local treatment for the new primary breast cancer currently under
             investigation (including surgery, radiotherapy, cytotoxic and endocrine treatments)

          -  Inadequate hematological or renal function

          -  Prothrombin time/international normalized ratio (INR) &gt;1.5 x ULN or outside
             therapeutic range if receiving anticoagulation that would affect the prothrombin
             time/INR

          -  Any of the following abnormal liver function test results: Aspartate aminotransferase
             &gt;1.5 x upper limit of normal (ULN); Alanine aminotransferase &gt;1.5 x ULN; Total
             bilirubin &gt;1.5 x ULN

          -  Participants are employees of the clinical study site or other individuals directly
             involved in the conduct of the study, or immediate family members of such individuals

          -  Sensitivity to any of the study interventions, or components thereof, or drug or other
             allergy that, in the opinion of the Investigator, contraindicates participation in the
             study

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>option 6</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 8400003</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400010</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400001</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400004</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400018</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400005</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400006</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400008</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400012</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0560003</name>
      <address>
        <city>Bruxelles</city>
        <zip>BE-1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0560001</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0560002</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500001</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500004</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500003</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800002</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800001</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800003</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400007</name>
      <address>
        <city>Hato Rey</city>
        <zip>00917</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6430002</name>
      <address>
        <city>Saint -Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6430003</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194156</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240003</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240001</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240002</name>
      <address>
        <city>Valencia / Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 5, 2019</study_first_submitted>
  <study_first_submitted_qc>December 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2019</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

